Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/Mavrilimumab> ?p ?o }
Showing triples 1 to 59 of
59
with 100 triples per page.
- Mavrilimumab abstract "Mavrilimumab is a human monoclonal antibody designed for the treatment of rheumatoid arthritis. It is an inhibitor of human granulocyte macrophage colony-stimulating factor receptor (GM-CSF-R).Mavrilimumab was discovered as CAM-3001 by Cambridge Antibody Technology and is being developed by MedImmune, Inc.It has so far shown positive results in phase 1 and phase 2a clinical trials. A phase 2a trial which studied mavrilimumab doses of up to 100 mg, reported that 55.7% of subjects met the primary endpoint of \"a ≥1.2 decrease from baseline in Disease Activity Score (DAS28-CRP) at week 12\" (vs. only 34.7% of placebo subjects). Two further clinical studies are reported to be underway in rheumatoid arthritis patients to investigate these effects further.Preliminary results, from a phase IIb study investigating doses of 30, 100 and 150 mg mavrilimumab over 24 weeks, were presented at a rheumatology conference in Rome, in August 2015. At week 24, 40.15% of patients in the top dose group achieved an ACR50 response compared to 3.7% in the placebo group. Rates of remission and low disease activity were reported to be significantly higher in the 150-mg group. Patients who completed this and a second US clinical study were enrolled into an open-label extension study to evaluate the longer term efficacy and safety of mavrilumumab for up to 74 weeks of treatment, presented at a rheumatology conference in San Francisco in November 2015. The authors concluded that 150 mg mavrilimumab was optimal for patients who had prior inadequate response to non-biological DMARDs compared to a dose of 100 mg every other week which had produced positive results in patients still receiving methotrexate.".
- Mavrilimumab atcPrefix "none".
- Mavrilimumab casNumber "1085337-57-0".
- Mavrilimumab fdaUniiCode "1158JD1P9A".
- Mavrilimumab wikiPageID "33024060".
- Mavrilimumab wikiPageLength "6118".
- Mavrilimumab wikiPageOutDegree "6".
- Mavrilimumab wikiPageRevisionID "707384872".
- Mavrilimumab wikiPageWikiLink Cambridge_Antibody_Technology.
- Mavrilimumab wikiPageWikiLink Category:Monoclonal_antibodies.
- Mavrilimumab wikiPageWikiLink Disease-modifying_antirheumatic_drug.
- Mavrilimumab wikiPageWikiLink Granulocyte_macrophage_colony-stimulating_factor_receptor.
- Mavrilimumab wikiPageWikiLink MedImmune.
- Mavrilimumab wikiPageWikiLink Rheumatoid_arthritis.
- Mavrilimumab wikiPageWikiLinkText "Mavrilimumab".
- Mavrilimumab wikiPageWikiLinkText "mavrilimumab".
- Mavrilimumab atcPrefix "none".
- Mavrilimumab c "6706".
- Mavrilimumab casNumber "1085337".
- Mavrilimumab chemspiderid "none".
- Mavrilimumab h "10438".
- Mavrilimumab iupharLigand "7785".
- Mavrilimumab mabType "mab".
- Mavrilimumab molecularWeight "143.2".
- Mavrilimumab n "1762".
- Mavrilimumab o "2104".
- Mavrilimumab s "54".
- Mavrilimumab source "u".
- Mavrilimumab target "GMCSF receptor &alpha-chain".
- Mavrilimumab type "mab".
- Mavrilimumab unii "1158".
- Mavrilimumab verifiedfields "changed".
- Mavrilimumab verifiedrevid "458637684".
- Mavrilimumab wikiPageUsesTemplate Template:Antineoplastic-drug-stub.
- Mavrilimumab wikiPageUsesTemplate Template:Cascite.
- Mavrilimumab wikiPageUsesTemplate Template:Chemspidercite.
- Mavrilimumab wikiPageUsesTemplate Template:Drugbankcite.
- Mavrilimumab wikiPageUsesTemplate Template:Drugbox.
- Mavrilimumab wikiPageUsesTemplate Template:Fdacite.
- Mavrilimumab wikiPageUsesTemplate Template:Monoclonal-antibody-stub.
- Mavrilimumab wikiPageUsesTemplate Template:Monoclonals_for_immune_system.
- Mavrilimumab subject Category:Monoclonal_antibodies.
- Mavrilimumab hypernym Antibody.
- Mavrilimumab type ChemicalSubstance.
- Mavrilimumab type Drug.
- Mavrilimumab type Antibody.
- Mavrilimumab type Chemical.
- Mavrilimumab type Drug.
- Mavrilimumab type ChemicalObject.
- Mavrilimumab type Thing.
- Mavrilimumab type Q8386.
- Mavrilimumab comment "Mavrilimumab is a human monoclonal antibody designed for the treatment of rheumatoid arthritis. It is an inhibitor of human granulocyte macrophage colony-stimulating factor receptor (GM-CSF-R).Mavrilimumab was discovered as CAM-3001 by Cambridge Antibody Technology and is being developed by MedImmune, Inc.It has so far shown positive results in phase 1 and phase 2a clinical trials.".
- Mavrilimumab label "Mavrilimumab".
- Mavrilimumab sameAs Q6794291.
- Mavrilimumab sameAs مافريليموماب.
- Mavrilimumab sameAs m.0h5479b.
- Mavrilimumab sameAs Q6794291.
- Mavrilimumab wasDerivedFrom Mavrilimumab?oldid=707384872.
- Mavrilimumab isPrimaryTopicOf Mavrilimumab.